Publication date: 

1 Apr 2015

Ref: 

Occup Med (Lond). 2015; 65(3): 256-8.

Author(s): 

Cannon J, Fitzgerald B, Seed M, Agius R, Jiwany A, Cullinan P.

Publication type: 

Article

Abstract: 

We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.